Audit of cabozantinib outcomes for metastatic renal cell carcinoma at Norfolk and Norwich University Hospital

被引：0

作者：

Kazmi, Farasat ^{[1
]}

Shanmugasundaram, Guhan ^{[1
]}

Prakash, Aravind ^{[1
]}

Taiwo, Olasumbo ^{[1
]}

Maskell, David ^{[1
]}

Wade, Robert ^{[1
]}

Kapur, Gaurav ^{[1
]}

机构：

[1] Norfolk & Norwich Univ Hosp NHS Fdn Trust, Norwich, England

来源：

CLINICAL ONCOLOGY | 2022年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E4 / E5

页数：13

共 2 条

[1]

Cancer Research UK, Kidney cancer statistics

[2] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial [J].

Choueiri, Toni K. ;

Escudier, Bernard ;

Powles, Thomas ;

Tannir, Nizar M. ;

Mainwaring, Paul N. ;

Rini, Brian I. ;

Hammers, Hans J. ;

Donskov, Frede ;

Roth, Bruce J. ;

Peltola, Katriina ;

Lee, Jae Lyun ;

Heng, Daniel Y. C. ;

Schmidinger, Manuela ;

Agarwal, Neeraj ;

Sternberg, Cora N. ;

McDermott, David F. ;

Aftab, Dana T. ;

Hessel, Colin ;

Old, Christian Scheff ;

Schwab, Gisela ;

Hutson, Thomas E. ;

Pal, Sumanta ;

Motzer, Robert J. .

LANCET ONCOLOGY, 2016, 17 (07) :917-927

← 1 →